Briefs: Torrent Pharmaceuticals and Laurus Synthesis

Laurus Synthesis receives Form 483 with 5 observations from USFDA

Briefs: J B Chemicals & Pharmaceuticals updates and Torrent Pharmaceuticals

The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat

Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023

Briefs: Man Industries, Jeevan Scientific Technology, Unichem and Torrent Pharmaceuticals

Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.

Torrent Pharmaceuticals posts Q3FY23 consolidated PAT at Rs. 283 Cr

The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022

Torrent Pharmaceuticals posts Q1FY23 consolidated PAT Rs. 354 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.

Torrent Pharmaceuticals consolidated PAT at Rs 249 cr

Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.

Torrent Pharmaceuticals Q1FY22 consolidated PAT up at Rs. 330 Cr

The company posted net profit of Rs.321 crores for the period ended June 30, 2020.

Ipca appoints Hitesh Kumar Maheshwari as President – R&D (Formulations)

He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company

Industry needs to establish a self-regulatory body to maintain the quality of the pharma products, says Dr Mandaviya